Entasis Therapeutics Holdings Inc (ETTX)


Stock Price Forecast

July 11, 2022


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Entasis Therapeutics Holdings Inc chart...

About the Company

Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis' pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections).

Exchange

NASDAQ

Website

www.entasistx.com

$7M

Total Revenue

47

Employees

$105M

Market Capitalization

-1.96

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ETTX News

Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S.

1mon ago, source: ADVFN

Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today the ...

Plc Astrazeneca's Net Worth

3d ago, source: Benzinga.com

Plc Astrazeneca has an estimated net worth of $812 Million. This is based on reported shares across multiple companies, which include Viela Bio, Inc., Aevi Genomic Medicine, Inc., PhaseBio ...

CERo Therapeutics Holdings Inc CERO

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Cerevel Therapeutics Holdings Inc

2mon ago, source: CNN

Cerevel Therapeutics Holdings, Inc. engages in the discovery and development of new therapies for neuroscience diseases. The firm's portfolio focuses on diseases such as schizophrenia, epilepsy ...

TPG Group Holdings (SBS) Advisors, Inc.'s Net Worth

1mon ago, source: Benzinga.com

Who is TPG Group Holdings (SBS) Advisors, Inc.? TPG Group Holdings (SBS) Advisors, Inc. has an estimated net worth of $36.8 Billion. This is based on reported shares across multiple companies ...

Arcturus Therapeutics Holdings, Inc.

2mon ago, source: CNN

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant ...

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript

19d ago, source: Yahoo Finance

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript February 28, 2024 G1 Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.27.

Rani Therapeutics Holdings Inc Class A RANI

19d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Arcturus Therapeutics Holdings, Inc.

2mon ago, source: CNN

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant ...

Rani Therapeutics Holdings, Inc. (RANI)

1y ago, source: Yahoo Finance

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...

Rani Therapeutics Holdings Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...